EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study

Meghan K. Gerety, Vivek Charu, Madison Simmons, Nicholas J. Seewald, Dorey A. Glenn, Douglas E. Schaubel, Abigail R. Smith, Dhruti Chen, Louis-Philippe Laurin, Michelle Denburg, Lawrence B. Holzman, Laurence H. Beck, Laura H. Mariani, Jarcy Zee

Kidney360 · 2026-10 · 7 (10) · 2324-2334

DOI: 10.34067/kid.0000001265 ↗
AbstractBibliografische Angaben

Abstract

Key Points Comparative treatment effects for rituximab and calcineurin inhibitors on real-world long-term outcomes were estimated. Rituximab was associated with better preservation of long-term kidney function in Cure Glomerulonephropathy patients with membranous nephropathy. Treatments captured real-world prescribing practices, and observations pertain to a broad, pragmatic population relevant to clinical practice. Background Clinical trials in rare glomerular disease may establish short-term treatment efficacy but are limited by small sample sizes and short study duration. Observational data are needed to assess longer-term outcomes and can provide insights into real-world prescribing practices. This study applied modern statistical methods to real-world data from the Cure Glomerulonephropathy network to compare the effectiveness of rituximab and calcineurin inhibitors on long-term primary membranous nephropathy outcomes. Methods CureGN participants with biopsy-confirmed primary membranous nephropathy who initiated either of the two treatments at least 6 months after any previous immunosuppressant exposure were eligible. Inverse probability-of-treatment weighting balanced covariates at treatment initiation. Inverse probability-of-censoring weights accounted for censoring individuals if another immunosuppressant was started during follow-up. Outcomes included time from treatment initiation to composite kidney disease progression (40% decline in eGFR, KRT, or eGFR

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →